Jim Cramer On Regeneron Pharmaceuticals Inc. (REGN) – “I Want You to Own It”
We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Pharma Stock to Buy According to Hedge Funds?
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Ocular rises as Needham issues new Buy on lead candidate
Ocular Therapeutix (NASDAQ:OCUL) stock rises as Needham rates the company a new Buy, citing the potential of its lead candidate, Axpaxli. Read more here.
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Investment Research on MSN10d
Bayer Q4 Earnings In Line, Revenues Top on Nubeqa, Kerendia Sales
Bayer AG BAYRY reported fourth-quarter 2024 core earnings of 28 cents per American Depositary Receipt (ADR), in line with the ...
Fierce Pharma10d
As Xarelto's decline picks up speed, Bayer doesn't expect pharma growth until 2027
While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...
kedglobal17d
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Earlier this month, the South Korean biosimilar maker secured approval for three other drugs from Europe: Eydenzelt, referencing blockbuster eye disease treatment Eylea; Stoboclo and Osenvelt.